

General Counsel

Medicines Patent Pool

Rue de Varembé 7 Geneva

1202 Switzerland

Date: 25th July, 2023

Subject: Termination of License Agreement

Dear Chan Park,

I hope this letter finds you well. On behalf of BrightGene Bio-Medical Technology Co. Ltd., we are writing to officially inform you of our decision to terminate the Molnupiravir License Agreement signed on 23/12/2021 (the "Agreement") with Medicines Patent Pool.

In accordance with clause 10.7 of the Agreement, we are exercising our right to terminate the Agreement by providing 30 days' written notice. This termination is a result of our internal strategic considerations and does not reflect any breach of the Agreement on either party's part.

Please consider this letter as our formal notice of termination in accordance with the provisions set forth in the Agreement. We remain open to discussing any questions you may have.

We would like to thank the Medicines Patent Pool for giving BrightGene Bio-Medical Technology Co. Ltd., the opportunity to license Molnupiravir and we hope to have other opportunities to collaborate in the future on other projects.

Best regards,

Dr. Yangqing Huang

R&D Director

BrightGene Bio-Medical Technology Co. Ltd.

